<DOC>
	<DOCNO>NCT00914602</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( PK ) , pharmacodynamics , safety XP21279 sustain release ( SR3 ) formulation [ administer Lodosyn® ( carbidopa ) ] Sinemet® tablet subject Parkinson 's disease Motor Fluctuations .</brief_summary>
	<brief_title>An Exploratory Study XP21279 ( With Lodosyn® ) Sinemet® Parkinson 's Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Subjects clinical diagnosis idiopathic Parkinson 's disease , confirm presence least two cardinal sign disease ( rest tremor , bradykinesia , rigidity ) . 2 . Subjects must predictable motor fluctuation wear type , define wear least 50 % interdose interval first last daily dos record on/off diary 3 day ( Days 4 2 ) Screening Period . 3 . Subjects must stable TID QID Sinemet® carbidopa/levodopa regimens morning early evening , total daily dose range 400 mg 1000 mg levodopa , least 1 week prior Screening . 1 . History , sign , symptom suggest diagnosis secondary atypical Parkinsonism . 2 . Subject great equal moderately disable dyskinesia great 25 % wake day assess score 2 item 32 score 2 item 33 UPDRS Screening . 3 . Subjects dose Sinemet® carbidopa/levodopa night time . 4 . Subjects significant neurological symptom account Parkinson 's disease . 5 . Subjects take concomitantly COMT inhibitor ( i.e. , entacapone tolcapone ) treat Stalevo® , Sinemet® CR , Madopar®/Prolopa® ( levodopa/benserazide ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>